Induction of Ca2+ signaling and cytotoxic responses of human lung fibroblasts upon an antihistamine drug oxatomide treatment and evaluating the protective effects of Ca2+ chelating.
Wei-Zhe Liang, Kai-Wei Hsieh, Zong-Da Yang, Gwo-Ching Sun
{"title":"Induction of Ca<sup>2+</sup> signaling and cytotoxic responses of human lung fibroblasts upon an antihistamine drug oxatomide treatment and evaluating the protective effects of Ca<sup>2+</sup> chelating.","authors":"Wei-Zhe Liang, Kai-Wei Hsieh, Zong-Da Yang, Gwo-Ching Sun","doi":"10.1111/fcp.13040","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oxatomide, an antihistamine drug of the diphenylmethylpiperazine family, has anti-inflammatory effects in airway disease. Because oxatomide was shown to cause diverse physiological responses in several cell models, the impact of oxatomide on Ca<sup>2+</sup> signaling and its related physiological effects has not been explored in IMR-90 human fetal lung fibroblasts.</p><p><strong>Objectives: </strong>This study assessed the effect of oxatomide on cell viability and intracellular free Ca<sup>2+</sup> concentrations ([Ca<sup>2+</sup>]<sub>i</sub>) and examined whether oxatomide-induced cytotoxicity through Ca<sup>2+</sup> signaling in IMR-90 cells.</p><p><strong>Methods: </strong>Cell viability was measured by the cell proliferation reagent (WST-1). [Ca<sup>2+</sup>]<sub>i</sub> was measured by the Ca<sup>2+</sup>-sensitive fluorescent dye fura-2.</p><p><strong>Results: </strong>Oxatomide (10-40 μM) concentration dependently reduced cell viability and induced [Ca<sup>2+</sup>]<sub>i</sub> rises in IMR-90 cells. This cytotoxic effect was reversed by chelation of cytosolic Ca<sup>2+</sup> with BAPTA-AM. In terms of Ca<sup>2+</sup> signaling, oxatomide-caused Ca<sup>2+</sup> entry was inhibited by modulators of store-operated Ca<sup>2+</sup> channels (2-APB and SKF96365) and protein kinase C (PKC) inhibitor (GF109203X). Furthermore, oxatomide-induced Ca<sup>2+</sup> influx was confirmed by Mn<sup>2+</sup>-induced quench of fura-2 fluorescence. In a Ca<sup>2+</sup>-free medium, preincubation with the endoplasmic reticulum Ca<sup>2+</sup> pump inhibitor thapsigargin inhibited oxatomide-evoked [Ca<sup>2+</sup>]<sub>i</sub> rises. Conversely, treatment with oxatomide abolished thapsigargin-induced [Ca<sup>2+</sup>]<sub>i</sub> rises. Inhibition of phospholipase C (PLC) with U73122 also inhibited oxatomide-caused [Ca<sup>2+</sup>]<sub>i</sub> rises.</p><p><strong>Conclusion: </strong>In IMR-90 cells, oxatomide-induced cytotoxicity by preceding [Ca<sup>2+</sup>]<sub>i</sub> rises involving PKC-sensitive store-operated Ca<sup>2+</sup> entry and PLC-dependent Ca<sup>2+</sup> release from the endoplasmic reticulum. BAPTA-AM, with its Ca<sup>2+</sup> chelating effects, may be a potential compound for preventing oxatomide-induced cytotoxicity.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental & Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/fcp.13040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Oxatomide, an antihistamine drug of the diphenylmethylpiperazine family, has anti-inflammatory effects in airway disease. Because oxatomide was shown to cause diverse physiological responses in several cell models, the impact of oxatomide on Ca2+ signaling and its related physiological effects has not been explored in IMR-90 human fetal lung fibroblasts.
Objectives: This study assessed the effect of oxatomide on cell viability and intracellular free Ca2+ concentrations ([Ca2+]i) and examined whether oxatomide-induced cytotoxicity through Ca2+ signaling in IMR-90 cells.
Methods: Cell viability was measured by the cell proliferation reagent (WST-1). [Ca2+]i was measured by the Ca2+-sensitive fluorescent dye fura-2.
Results: Oxatomide (10-40 μM) concentration dependently reduced cell viability and induced [Ca2+]i rises in IMR-90 cells. This cytotoxic effect was reversed by chelation of cytosolic Ca2+ with BAPTA-AM. In terms of Ca2+ signaling, oxatomide-caused Ca2+ entry was inhibited by modulators of store-operated Ca2+ channels (2-APB and SKF96365) and protein kinase C (PKC) inhibitor (GF109203X). Furthermore, oxatomide-induced Ca2+ influx was confirmed by Mn2+-induced quench of fura-2 fluorescence. In a Ca2+-free medium, preincubation with the endoplasmic reticulum Ca2+ pump inhibitor thapsigargin inhibited oxatomide-evoked [Ca2+]i rises. Conversely, treatment with oxatomide abolished thapsigargin-induced [Ca2+]i rises. Inhibition of phospholipase C (PLC) with U73122 also inhibited oxatomide-caused [Ca2+]i rises.
Conclusion: In IMR-90 cells, oxatomide-induced cytotoxicity by preceding [Ca2+]i rises involving PKC-sensitive store-operated Ca2+ entry and PLC-dependent Ca2+ release from the endoplasmic reticulum. BAPTA-AM, with its Ca2+ chelating effects, may be a potential compound for preventing oxatomide-induced cytotoxicity.
期刊介绍:
Fundamental & Clinical Pharmacology publishes reports describing important and novel developments in fundamental as well as clinical research relevant to drug therapy. Original articles, short communications and reviews are published on all aspects of experimental and clinical pharmacology including:
Antimicrobial, Antiviral Agents
Autonomic Pharmacology
Cardiovascular Pharmacology
Cellular Pharmacology
Clinical Trials
Endocrinopharmacology
Gene Therapy
Inflammation, Immunopharmacology
Lipids, Atherosclerosis
Liver and G-I Tract Pharmacology
Metabolism, Pharmacokinetics
Neuropharmacology
Neuropsychopharmacology
Oncopharmacology
Pediatric Pharmacology Development
Pharmacoeconomics
Pharmacoepidemiology
Pharmacogenetics, Pharmacogenomics
Pharmacovigilance
Pulmonary Pharmacology
Receptors, Signal Transduction
Renal Pharmacology
Thrombosis and Hemostasis
Toxicopharmacology
Clinical research, including clinical studies and clinical trials, may cover disciplines such as pharmacokinetics, pharmacodynamics, pharmacovigilance, pharmacoepidemiology, pharmacogenomics and pharmacoeconomics. Basic research articles from fields such as physiology and molecular biology which contribute to an understanding of drug therapy are also welcomed.